Long Noncoding RNA ZFAS1 Enhances Adriamycin Resistance in Pediatric Acute Myeloid Leukemia Through the MiR-195/Myb Axis

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 9

PMID 35530496

Authors

Qun Li

Jianmin Wang

Affiliations

Soon will be listed here.

Abstract

: Development of chemoresistance remains a major obstacle for pediatric acute myeloid leukemia (AML) management. Zinc finger antisense 1 (ZFAS1) is a novel tumor-related lncRNA that has been reported as an oncogene involved in the development of pediatric AML. The purpose of the present study was to investigate the role and underlying mechanism of ZFAS1 in AML chemoresistance. : The expression levels of ZFAS1 and miR-195 were assessed by qRT-PCR and Myb expression was detected using western blotting. The CCK-8 assay was used to determine the IC value for adriamycin (ADR) and cell proliferation. Cell apoptosis was measured by flow cytometry. The targeted interaction between miR-195 and ZFAS1 or Myb was evaluated by the dual-luciferase reporter assay or RNA immunoprecipitation assay. : Our data revealed that ADR treatment induced ZFAS1 expression in pediatric AML. Silencing of ZFAS1 or Myb alleviated AML cell resistance to ADR . ZFAS1 directly targeted miR-195 and negatively modulated miR-195 expression. Myb was a direct target of miR-195. Moreover, the inhibitory effect of ZFAS1 silencing on ADR resistance of AML cells was mediated by miR-195 . Myb was involved in the regulation of the ZFAS1/miR-195 axis in ADR resistance of AML cells. : Our data indicated that ZFAS1 silencing alleviated ADR resistance of AML cells through acting as a sponge for miR-195 and regulating Myb expression. Targeting ZFAS1 might be a promising therapeutic strategy for pediatric AML treatment.

Citing Articles

Overexpression and oncogenic role of RIPK3 in acute myeloid leukemia associated with specific subtypes and treatment outcome.

Wang Y, Zhang T, Zhang L, Xu Z, Chu M, Zhao Y BMC Cancer. 2025; 25(1):253.

PMID: 39948488 PMC: 11827379. DOI: 10.1186/s12885-025-13613-2.

The role of long noncoding RNAs in the diagnosis, prognosis and therapeutic biomarkers of acute myeloid leukemia.

Atnaf A, Akelew Y, Abebaw D, Muche Y, Getachew M, Mengist H Ann Hematol. 2024; 103(12):4931-4942.

PMID: 39264436 DOI: 10.1007/s00277-024-05987-3.

Glycolysis and chemoresistance in acute myeloid leukemia.

Yang Y, Pu J, Yang Y Heliyon. 2024; 10(15):e35721.

PMID: 39170140 PMC: 11336864. DOI: 10.1016/j.heliyon.2024.e35721.

MiRNA expression as outcome predictor in pediatric AML: systematic evaluation of a new model.

Ellson I, Martorell-Marugan J, Carmona-Saez P, Ramos-Mejia V NPJ Genom Med. 2024; 9(1):40.

PMID: 39107334 PMC: 11303725. DOI: 10.1038/s41525-024-00424-w.

Silencing LINC00987 ameliorates adriamycin resistance of acute myeloid leukemia via miR-4458/HMGA2 axis.

Liu Y, Zhu X, Liao L, Zhang Z, Huang T, Zhang L Biol Direct. 2024; 19(1):49.

PMID: 38910243 PMC: 11195003. DOI: 10.1186/s13062-024-00490-1.

References

Pattabiraman D, Gonda T . Role and potential for therapeutic targeting of MYB in leukemia. Leukemia. 2012; 27(2):269-77. DOI: 10.1038/leu.2012.225. View

Creutzig U, Zimmermann M, Bourquin J, Dworzak M, Fleischhack G, Graf N . Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013; 122(1):37-43. DOI: 10.1182/blood-2013-02-484097. View

Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L . Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol. 2010; 85(5):331-9. DOI: 10.1002/ajh.21667. View

Kaspers G . Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2012; 12(3):405-13. DOI: 10.1586/era.12.1. View

Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z . Amplification of Long Noncoding RNA ZFAS1 Promotes Metastasis in Hepatocellular Carcinoma. Cancer Res. 2015; 75(15):3181-91. DOI: 10.1158/0008-5472.CAN-14-3721. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Xie S, Ge Q, Wang X, Sun X, Kang Y . Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer. Cell Cycle. 2017; 17(2):154-161. PMC: 5884120. DOI: 10.1080/15384101.2017.1407895. View

Li Q, Song W, Wang J . TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. Biomed Pharmacother. 2018; 109:1793-1801. DOI: 10.1016/j.biopha.2018.11.003. View

Liu Q, Ma H, Sun X, Liu B, Xiao Y, Pan S . The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia. J Exp Clin Cancer Res. 2019; 38(1):199. PMC: 6524305. DOI: 10.1186/s13046-019-1208-x. View

10.

Brown F, Cifani P, Drill E, He J, Still E, Zhong S . Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol. 2016; 176(1):86-91. PMC: 5177472. DOI: 10.1111/bjh.14413. View

11.

Feng L, Shen F, Zhou J, Chen Y . Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity. Gene. 2019; 696:105-112. DOI: 10.1016/j.gene.2019.01.025. View

12.

Liu X, Sun M, Nie F, Ge Y, Zhang E, Yin D . Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014; 13:92. PMC: 4021402. DOI: 10.1186/1476-4598-13-92. View

13.

Rasche M, Zimmermann M, Borschel L, Bourquin J, Dworzak M, Klingebiel T . Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018; 32(10):2167-2177. PMC: 6170392. DOI: 10.1038/s41375-018-0071-7. View

14.

Gibb E, Brown C, Lam W . The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011; 10:38. PMC: 3098824. DOI: 10.1186/1476-4598-10-38. View

15.

Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y . MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett. 2014; 347(1):65-74. DOI: 10.1016/j.canlet.2014.01.019. View

16.

Askarian-Amiri M, Crawford J, French J, Smart C, Smith M, Clark M . SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. RNA. 2011; 17(5):878-91. PMC: 3078737. DOI: 10.1261/rna.2528811. View

17.

Xing C, Hu X, Xie F, Yu Z, Li H, Bin-Zhou . Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia. FEBS Lett. 2015; 589(15):1981-7. DOI: 10.1016/j.febslet.2015.04.061. View

18.

Gan S, Ma P, Ma J, Wang W, Han H, Chen L . Knockdown of ZFAS1 suppresses the progression of acute myeloid leukemia by regulating microRNA-150/Sp1 and microRNA-150/Myb pathways. Eur J Pharmacol. 2018; 844:38-48. DOI: 10.1016/j.ejphar.2018.11.036. View

19.

Fatica A, Bozzoni I . Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2013; 15(1):7-21. DOI: 10.1038/nrg3606. View

20.

Ye R, Wei B, Li S, Liu W, Liu J, Qiu L . Expression of miR-195 is associated with chemotherapy sensitivity of cisplatin and clinical prognosis in gastric cancer. Oncotarget. 2017; 8(57):97260-97272. PMC: 5722560. DOI: 10.18632/oncotarget.21919. View